[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Engene Therapeutics Inc (ENGN)

Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,913
  • Shares Outstanding, K 66,985
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,300 K
  • EBIT $ -133 M
  • EBITDA $ -135 M
  • 60-Month Beta -0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.50

Options Overview Details

View History
  • Implied Volatility 84.04% (+11.71%)
  • Historical Volatility 47.95%
  • IV Percentile 18%
  • IV Rank 13.39%
  • IV High 318.88% on 04/28/26
  • IV Low 47.74% on 06/15/26
  • Expected Move (DTE 25) 0.2125 (11.68%)
  • Put/Call Vol Ratio 1.73
  • Today's Volume 458
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 1.49
  • Today's Open Interest 7,869
  • Open Int (30-Day) 7,622
  • Expected Range 1.6075 to 2.0325

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 4
  • High Estimate $-0.40
  • Low Estimate $-0.55
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) +17.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7200 +5.81%
on 06/29/26
1.9600 -7.14%
on 07/15/26
+0.0700 (+4.00%)
since 06/24/26
3-Month
1.4000 +30.00%
on 05/12/26
9.0000 -79.78%
on 05/06/26
-6.1700 (-77.22%)
since 04/24/26
52-Week
1.4000 +30.00%
on 05/12/26
12.2500 -85.14%
on 01/23/26
-1.8700 (-50.68%)
since 07/24/25

Most Recent Stories

More News
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA)...

ENGN : 1.8200 (-3.70%)
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for...

ENGN : 1.8200 (-3.70%)
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics...

ENGN : 1.8200 (-3.70%)
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics...

ENGN : 1.8200 (-3.70%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised...

ENGN : 1.8200 (-3.70%)
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. (“enGene” or “the Company”)...

ENGN : 1.8200 (-3.70%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised...

ENGN : 1.8200 (-3.70%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised...

ENGN : 1.8200 (-3.70%)
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive...

ENGN : 1.8200 (-3.70%)
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) ...

ENGN : 1.8200 (-3.70%)

Business Summary

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

See More

Key Turning Points

3rd Resistance Point 1.9500
2nd Resistance Point 1.9200
1st Resistance Point 1.8700
Last Price 1.8200
1st Support Level 1.7900
2nd Support Level 1.7600
3rd Support Level 1.7100

See More

52-Week High 12.2500
Fibonacci 61.8% 8.1053
Fibonacci 50% 6.8250
Fibonacci 38.2% 5.5447
Last Price 1.8200
52-Week Low 1.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.